Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

Onc.AI, a digital health company developing AI-powered oncology clinical management solutions, today announced that new validation study results from research collaborations with Pfizer, Baylor Scott ...

Cancer remains one of the biggest health challenges of our lifetime. Millions of people globally receive a cancer diagnosis each year — in the United States, that’s about one diagnosis every 30 ...

Zenlayer, the world's hyperconnected cloud, today announced it has been named Global Partner of the Year for 2024 by Equinix, the world's digital infrastructure company®. Zenlayer earned this ...

Pfizer's BRAFTOVI combo cut death risk by 51% and more than doubled survival in BRAF-mutant colorectal cancer in a Phase 3 ...

Pfizer (PFE) stock gains as Braftovi combo shows survival benefits in a late-stage trial for metastatic colorectal cancer ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

At the heart of the deal is an anti-Claudin18.2 antibody-drug conjugate being developed for solid tumors, including gastric ...

The Novel Drug Delivery System Market is experiencing a transformative boom, fueled by advances in nanotechnology, targeted ...

Market is projected to reach a multimillion-dollar valuation by 2034, driven by an unexpected compound annual growth rate (5.64) from 2025 to 2034.

The annual meeting of the American Society of Clinical Oncology is the most visible showcase for new cancer drug data. Join industry leaders, scientific experts, and STAT reporters for an ...